Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06106672
Other study ID # CNP-106-5.001
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date May 30, 2024
Est. completion date August 2026

Study information

Verified date June 2024
Source COUR Pharmaceutical Development Company, Inc.
Contact Jason Penix
Phone 773-339-5745
Email jpenix@courpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106.


Description:

This is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-106. The clinical study lasts 222-days (up to 42 days for Screening, 180 Study Days). Subjects ages 18-75 with generalized myasthenia gravis (MG) will be screened up to 42 days prior to enrollment into the clinical study.


Recruitment information / eligibility

Status Recruiting
Enrollment 54
Est. completion date August 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Subjects who are willing and able to provide Institutional Review Board (IRB) approved written informed consent and privacy language as per national regulations. 2. Men and non-pregnant women, ages 18-75 years inclusive. 3. Female subjects of childbearing potential must agree not to become pregnant during the clinical study, have a negative pregnancy test at the Screening Visit, and agree to one of the following: - Use two highly effective forms of birth control starting at initial screening and continuing throughout the study duration. - Practice abstinence starting at initial screening and continuing throughout the study duration. 4. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class III-IV (Cohort 1). Upon successful DMC review and approval of preliminary safety data obtained from Cohort 1 through Day 15, Cohort 2 will enroll subjects with MGFA Clinical Classification Class II-IV. 5. Subjects positive for anti-AChR antibodies by radioimmunoassay (RIA) (Mayo Clinic). 6, Subjects with MG-ADL Score = 6 at Screening and Baseline Visit with = 50% of the score derived from non-ocular symptoms. 7. Subjects with QMG Score = 11 at Screening and Baseline Visit. 8. For subjects on any medication used to treat the symptoms of MG (ex. Corticosteroids, pyridostigmine), subjects must be on a stable dose for a minimum of 90 days prior to enrollment and must agree not to increase their dose through clinical study duration unless reviewed and approved by the medical monitor and the site investigator. 9. Female subjects who agree to not breastfeed starting at initial screening and throughout the study duration. 10. Female subjects who agree to not donate ova starting at initial screening and throughout the study duration. 11. Male subjects with a spouse or partner of childbearing potential, who themselves and their spouse or partner agree to practice an effective form of birth control as discussed with the study doctor or study staff starting at Screening and throughout the study duration. Exclusion Criteria: 1. Subjects with a Myasthenia Gravis Foundation of America Clinical Classification Class I or V. 2. Subjects with a history of cerebrovascular accident in the past 12 months. 3. Subjects with MG-ADL Score < 6 at Screen or Subjects with MG-ADL Score = 6 at Screen with ? 50% of the score derived from non-ocular symptoms. 4. Subjects with QMG Score < 11 at Screen. 5. Subjects who have used the following medications: - Tacrolimus within 6 months prior to the first dosing; - Methotrexate within 5 half-lives or 90 days after last dose (whichever is longer); - Anti-FcRn inhibitors (ex. Efgartigimod) within 5 half-lives or 90 days after last dose (whichever is longer); - C5 complement inhibitor (ex. Eculizumab) within 5 half-lives or 90 days after last dose (whichever is longer); - Anti-CD20 (ex. Rituximab) within 5 half-lives for 90 days after last dose (whichever is longer); - Inclusion of subjects on other immunomodulatory drugs will be at the discretion of the medical monitor and study site investigator. 6. Subjects who have used immunoglobulins given SC or IV (SCIg or IVIg) or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening. 7. Subjects who have had thymectomy or any other thymic surgery performed within 12 months prior to Screening. 8. Subjects with untreated thymic malignancy, carcinoma, or thymoma. 9. Subjects with a history of tuberculosis or positive PPD skin test. 10. Subjects who have received administration of any live vaccine (other than intranasal Influenza) within 28 days or subunit vaccine within 14 days prior to Screening or are planning to receive any vaccination throughout the study duration. 11. Subjects who have received any COVID-19 vaccine within 14 days prior to Screening. Subjects who have received the first dose of any COVID-19 vaccine may not screen for the study until 14 days following their last dose of the vaccine if applicable. 12. Subjects with laboratory test results at Screening or prior to study dosing that are outside the normal limits and considered by the investigator to be clinically significant. Note: Clinically significant laboratory test results at screening that are related to the condition (MG) are acceptable as long as all inclusion and no other exclusion criteria are met. 13. Subjects with positive test results for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, or human immunodeficiency virus (HIV) antigen/antibody as determined at Screening. 14. Subjects with a history of or currently active immune disorders other than MG (including autoimmune disease) unless the condition, after discussion with the medical monitor and study site investigator, has been deemed to be acceptable for the subject's participation in this clinical study. 15. Subjects with a history of or current active diseases other than myasthenia gravis requiring immunosuppressive drugs (including azathioprine, prednisone, prednisolone, budesonide, cyclosporine, tacrolimus, methotrexate, or mycophenolate mofetil) unless the condition, after discussion with the medical monitor and site investigator, has been deemed to be acceptable for the subject's participation in this clinical study. 16. Subjects with a clinical history of significant cardiovascular disease as determined by the Investigator. 17. Subjects with a complication or medical history of malignancy within the past 5 years which, in the investigator's opinion, makes the subject unsuitable for study participation. 18. Subjects with a history of mast cell activation disease. 19. Subjects who, in the investigator's opinion, will be unable to adhere to study procedures. 20. Subjects who have received an investigational therapy other than CNP-106 within 28 days or 5 half-lives, whichever is longer, prior to Screening. 21. Subjects with any known active condition which, in the investigator's opinion, makes the subject unsuitable for study participation. 22. Known sensitivity to any components of CNP-106 (PLGA, sucrose, mannitol or sodium citrate).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CNP-106
CNP-106 is comprised of an antigenic AChR Peptide Pool (~1 µg of each AChRa and AChRe peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
Other:
Placebo
CNP-106 Placebo

Locations

Country Name City State
United States Infusion for Health Brea California
United States Medical University of South Carolina Charleston South Carolina
United States Ohio State University Wexner Medical Center Columbus Ohio
United States Nerve and Muscle Center of Texas Houston Texas
United States University of Kansas Medical Center Kansas City Kansas
United States Quantix Research, LLC Miami Florida
United States University of Minnesota Minneapolis Minnesota
United States Yale University New Haven Connecticut
United States University of California, Irvine Orange California
United States Barrow Neurological Institute Phoenix Arizona
United States Neuromuscular Clinic and Research Center Phoenix Arizona
United States Virginia Commonwealth University Richmond Virginia
United States University of South Florida Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
COUR Pharmaceutical Development Company, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs), Frequency tables will be presented by treatment group for all AEs and SAEs by System Organ Class (SOC) and Preferred Term (PT). Frequency tables will also be produced by treatment group for AEs leading to COUR Pharmaceuticals Development Company, Inc. Confidential CNP-106-5.001 Protocol; IND 28774 Page 53 of 65 discontinuation from IP and study, by severity, and by causality. No formal statistical testing will be done. Through study day 180
Secondary Change from baseline in antigen specific CD4+ and CD8+ T cell levels in PBMC at Day 60, 90, and 180. The mean change from Baseline to the endpoint within CNP-106 and Placebo treatment groups will be analyzed using ANOVA. Through study day 180
Secondary Change from baseline in activated antigen specific CD4+ and CD8+ T cell levels in PBMC at Day 60, 90, and 180. The mean change from Baseline to the endpoint within CNP-106 and Placebo treatment groups will be analyzed using ANOVA. Through study day 180
See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche